Z A Uc1, S Gorar2, S Mizrak3, S Gullu4. 1. Department of Endocrinology, Usak University School of Medicine, Usak, Turkey. ziynetalp@yahoo.com. 2. Department of Endocrinology, Antalya Training and Research Hospital, Antalya, Turkey. 3. Department of Biochemistry, Usak University School of Medicine, Usak, Turkey. 4. Department of Endocrinology, Ankara University School of Medicine, Ankara, Turkey.
Abstract
PURPOSE: Irisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a profound influence on the metabolism of human body. Therefore, the aim of this study was to investigate the possible changes in serum irisin concentrations before and after treatment in hypothyroid subjects. METHODS: The study included 26 patients with overt hypothyroidism due to Hashimoto thyroiditis and 19 healthy subjects. Baseline serum thyroid function tests and presence of thyroid autoantibodies and levels of creatine kinase (CK) and irisin were measured in both groups. All measurements in the hypothyroid group were repeated after euthyroidism was achieved. RESULTS: Serum irisin levels were significantly lower in the hypothyroid groups than the control group (p < 0.001). Negative correlation between irisin and thyroid stimulating hormone and CK levels (r = - 0.623, p < 0.001 and r = - 0.389, p = 0.008, respectively) and a positive correlation between irisin and free thyroxine (fT4) levels (r = 0.570, p < 0.001) was found. Serum CK levels decreased significantly after treatment (p < 0.001). Serum irisin levels significantly increased (from 57.4 to 99.8 U/L, p < 0.001) when the hypothyroid patients were treated to achieve euthyroidism. CONCLUSIONS: To the best of our knowledge, this is the first study providing insight that low serum irisin levels significantly increased following treatment to euthyroid state in overt hypothyroid patients with Hashimoto thyroiditis. Larger scale studies are needed to confirm these results and to ensure irisin as a possible biomarker of Hashimoto's thyroiditis.
PURPOSE:Irisin is a newly identified myokine secreted by skeletal muscle and has significant effects on body metabolism. Thyroidal functional state has a profound influence on the metabolism of human body. Therefore, the aim of this study was to investigate the possible changes in serum irisin concentrations before and after treatment in hypothyroid subjects. METHODS: The study included 26 patients with overt hypothyroidism due to Hashimoto thyroiditis and 19 healthy subjects. Baseline serum thyroid function tests and presence of thyroid autoantibodies and levels of creatine kinase (CK) and irisin were measured in both groups. All measurements in the hypothyroid group were repeated after euthyroidism was achieved. RESULTS: Serum irisin levels were significantly lower in the hypothyroid groups than the control group (p < 0.001). Negative correlation between irisin and thyroid stimulating hormone and CK levels (r = - 0.623, p < 0.001 and r = - 0.389, p = 0.008, respectively) and a positive correlation between irisin and free thyroxine (fT4) levels (r = 0.570, p < 0.001) was found. Serum CK levels decreased significantly after treatment (p < 0.001). Serum irisin levels significantly increased (from 57.4 to 99.8 U/L, p < 0.001) when the hypothyroidpatients were treated to achieve euthyroidism. CONCLUSIONS: To the best of our knowledge, this is the first study providing insight that low serum irisin levels significantly increased following treatment to euthyroid state in overt hypothyroidpatients with Hashimoto thyroiditis. Larger scale studies are needed to confirm these results and to ensure irisin as a possible biomarker of Hashimoto's thyroiditis.
Authors: W Edward Visser; Karen A Heemstra; Sigrid M A Swagemakers; Zeliha Ozgür; Eleonora P Corssmit; Jacobus Burggraaf; Wilfred F J van Ijcken; Peter J van der Spek; Johannes W A Smit; Theo J Visser Journal: J Clin Endocrinol Metab Date: 2009-06-30 Impact factor: 5.958
Authors: Joo Young Huh; Grigorios Panagiotou; Vassilis Mougios; Mary Brinkoetter; Maria T Vamvini; Benjamin E Schneider; Christos S Mantzoros Journal: Metabolism Date: 2012-09-25 Impact factor: 8.694
Authors: D Gallo; E Piantanida; G Veronesi; A Lai; L Sassi; V Lombardi; E Masiello; P Premoli; E Bianconi; C Cusini; S Rosetti; M L Tanda; A Toniolo; M Ferrario; L Bartalena Journal: J Endocrinol Invest Date: 2017-04-22 Impact factor: 4.256
Authors: Michael D Roberts; David S Bayless; Joseph M Company; Nathan T Jenkins; Jaume Padilla; Thomas E Childs; Jeffrey S Martin; Vincent J Dalbo; Frank W Booth; R Scott Rector; M Harold Laughlin Journal: Metabolism Date: 2013-03-14 Impact factor: 8.694
Authors: Pontus Boström; Jun Wu; Mark P Jedrychowski; Anisha Korde; Li Ye; James C Lo; Kyle A Rasbach; Elisabeth Almer Boström; Jang Hyun Choi; Jonathan Z Long; Shingo Kajimura; Maria Cristina Zingaretti; Birgitte F Vind; Hua Tu; Saverio Cinti; Kurt Højlund; Steven P Gygi; Bruce M Spiegelman Journal: Nature Date: 2012-01-11 Impact factor: 49.962
Authors: R Bocale; A Barini; A D'Amore; M Boscherin; S Necozione; A Barini; G Desideri; C P Lombardi Journal: J Endocrinol Invest Date: 2020-10-14 Impact factor: 4.256